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Hepatic veno-occlusive disease (VOD), also called sinusoidal obstruction syndrome, 
is rapidly progressing and involves life-threatening complications that can occur in 
patients receiving chemotherapy and/or bone marrow transplantation. No completely 
satisfactory treatment strategies have yet been established. We present a case of 
rhabdomyosarcoma in a 21-month-old boy who developed pancytopenia, dyspnea, 
jaundice, massive ascites and body weight gain of more than 10% after receiving con-
ventional chemotherapy. Hepatic VOD was diagnosed. He recovered after supportive 
care and treatment with high-dose methylprednisolone.
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Hepatic veno-occlusive disease (VOD) is a well-known 
complication of conditioning regimens used for stem-
cell transplantation.1−3 Its incidence varies from less 
than 5% to as high as 70% in different reports.2 The 
pathogenesis of VOD was once considered to be due 
to obstruction of hepatic venules and small sublob-
ular veins by microthromboses.4 Recent studies have 
suggested that the primary toxic injury to sinusoidal 
endothelial cells, followed by a series of biologic 
processes, leads to circulatory compromise of the 
centrilobular hepatocytes, fibrosis, and obstruction 
of liver blood flow.5 Thus, sinusoidal obstruction 
syndrome seems a more appropriate term.
Recently, VOD has been increasingly recognized 
as a complication of conventional chemotherapy, 
with or without abdominal irradiation, especially 
in patients with Wilms’ tumor treated with dactin-
omycin.6 There are currently no satisfactory treat-
ments available. We present our experience with a 
young boy with hepatic VOD who was treated suc-
cessfully with high-dose methylprednisolone (HDMT).
2. Case Report
A 21-month-old male patient initially presented with 
a left submandibular mass with extension to the 
ipsilateral periauricular area. Yellowish discharge and 
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bleeding were noted in the left ear canal. He was 
brought to a local hospital, where head and neck 
computed tomography revealed a 5 × 4-cm mass with 
central hypodensity and encroachment of the left fa-
cial nerve. He was transferred to our hospital, and 
rhabdomyosarcoma, Intergroup Rhabdomyosarcoma 
Study Group III, was diagnosed by histologic examina-
tion. Chemotherapy, consisting of vincristine 1.5 mg/
m2/day on Day 1, dactinomycin 0.5 mg/m2/day on 
Days 1−5, and cyclophosphamide 2.2 g/m2/day on 
Day 1 (i.e., the VAC regimen) and alternating with 
vincristine 1.5 mg/m2/day on Day 1, etoposide 100 mg/
m2/day on Days 1−5, and 1.8 g/m2/day ifosfamide on 
Days 1−5 (i.e., the VEI regimen), was administered 
every 3 weeks. The first courses of VAC and VEI che-
motherapy were uneventful, except for the devel-
opment of pancytopenia and neutropenic fever.
The patient developed fever and abdominal dis-
tension on the third day (Day + 8 from the start of 
chemotherapy) after completing the second course 
of the VAC regimen. A complete blood count re-
vealed pancytopenia (white blood cells [WBC], 500/
mm3; hemoglobin [Hb], 9.6 g/dL; platelets, < 3000/
mm3). C-reactive protein (CRP) was 2.8 mg/dL. A 
chest X-ray showed right-sided pleural effusion. 
Empiric antibiotics were prescribed after septic 
workup. The patient’s condition worsened rapidly 
on Day + 11, and he was transferred to the pediatric 
intensive care unit because of dyspnea. His body 
weight had increased by more than 10% (from 12.9 to 
15 kg). Laboratory tests showed WBC < 200/mm3, Hb 
of 6.0 g/dL, platelet count of 1000/mm3, aspartate 
aminotransferase (AST) of 118 U/L, alanine amino-
transferase (ALT) of 54 U/L, total bilirubin of 1.1 g/
dL, direct bilirubin of 0.51 g/dL, blood urea nitro-
gen (BUN) < 1 mg/dL, creatinine (Cr) of 0.2 mg/dL, Na 
of 136 mmol/L, K of 3.6 mmol/L, Cl of 102 mmol/L, 
and albumin of 3 g/dL. Activated partial thrombo-
plastin time was normal, prothrombin time was 
prolonged (13.7 seconds) (international normalized 
ratio [INR] = 1.29), fibrinogen was 174 mg/dL, and 
D-dimer was 1987 μg/L. Arterial blood gas showed 
pH 7.457, pCO2 of 44.6 mmHg, pO2 of 59.4 mmHg, 
bicarbonate of 30.8 mmol/L, and O2sat of 91.9%, 
with a 50% O2 hood in use. A follow-up chest X-ray 
revealed bilateral lower lung infiltration with bilat-
eral pleural effusion. Abdominal sonography showed 
hepatomegaly and massive ascites. The blood flow 
of the hepatic vein and inferior vena cava was dif-
ficult to detect because of massive ascites. In spite 
of blood component replacement (platelet concen-
trates, fresh frozen plasma and leukocyte-poor 
packed red blood cells), fluid restriction, and diuret-
ics, the patient’s clinical condition failed to improve. 
VOD was diagnosed based on the above findings, 
and HDMT (15 mg/kg, every 12 hours for six doses) 
was given, beginning on the evening of Day +12.
The morning after initiation of HDMT (Day +13), 
serum AST, ALT, and total bilirubin were elevated 
to 459 U/L, 199 U/L, and 2.4 g/dL, respectively. Pro-
thrombin time was prolonged further (16.5 sec-
onds; INR = 1.56). BUN was 3 mg/dL and Cr 0.4 mg/
dL. On the morning of Day + 14, serum AST, ALT, total 
bilirubin, BUN, and Cr were 1108 U/L, 489 U/L, 2.9 g/
dL, 5 mg/dL, and 0.5 mg/dL, respectively, and by 
Day + 15, serum AST, ALT, total bilirubin and direct 
bilirubin had risen to 1494 U/L, 781 U/L, 3.4 g/dL, 
and 1.51 g/dL, respectively. Thereafter, the patient’s 
condition improved gradually. One week later 
(Day + 20), serum AST, ALT and total bilirubin had 
returned to 91 U/L, 197 U/L, and 1.4 g/dL, respec-
tively. Blood and urine cultures were sterile. The 
highest CRP level during this period was 32.7 mg/
dL. Work-ups for hepatitis A, B, C, and cytomega-
lovirus were all negative. Neither side effects due 
to HDMT nor sequelae of VOD were noted. After 
the patient’s general condition had improved and 
the laboratory data returned to normal, the VAC 
regimen was replaced by the VEC regimen (vincris-
tine 2 mg/m2/day on Day 1, epirubicin 30 mg/m2/
day on Days 1−2, and cyclophosphamide 10 mg/
m2/day on Days 1−3) because of refusal of further 
VAC treatment by the patient’s family. Follow-up 
liver function tests were within normal limits, and 
abdominal echography was negative for abnormal 
findings up to the completion of a 1-year course of 
chemotherapy.
3. Discussion
The gold standard for the diagnosis of VOD is based 
on histological examination of liver tissue. However, 
this is often not feasible due to coexisting refractory 
thrombocytopenia and coagulopathy.2,4,7 Clinical 
criteria for the diagnosis of VOD have been drafted 
by Seattle and Baltimore groups.8,9 According to the 
Seattle criteria, two of the three signs (jaundice, 
painful hepatomegaly and fluid retention) must be 
present. The Baltimore criteria include jaundice 
(total bilirubin > 2 mg/dL) plus at least two of the 
following signs: hepatomegaly (usually painful), as-
cites and > 5% weight gain. Our case fulfilled the cri-
teria of both groups. However, the diagnosis of VOD 
must be carefully differentiated from those of sep-
sis, viral hepatitis, fungal infection, drug-related cho-
lestasis and hepatotoxicity, and tumor infiltration.
The severity of VOD is defined retrospectively 
following clinical observations. Mild VOD resolves 
without intervention; moderate VOD requires med-
ical treatment but is resolved completely; severe 
VOD progresses to multiorgan failure or causes 
death.1,3 Multiorgan failure is defined as either oxy-
gen requirement with an oxygen saturation of 90% 
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or less on room air and/or ventilator depen dence; 
and/or renal dysfunction (defined as a doubling of 
baseline creatinine and/or dialysis dependence); 
and/or encephalopathy, in addition to liver failure. 
However, this model can only provide a retrospective 
assessment of severity.
Many groups have reported an increased risk of 
VOD after bone marrow transplantation, but infor-
mation about the effects of conventional chemo-
therapy is still scarce. Arndt et al cited age as the 
greatest risk factor for the development of hepat-
opathy after VAC therapy.10 In their study, the risk 
of hepatopathy was 4% in children 3 years of age or 
older, and climbed to 15% in patients under 3 years of 
age. Furthermore, in the children under 3 years old, 
only one patient was less than 1 year old; all oth-
ers were between 1 and 3 years of age. The che-
motherapy dose used in the patients younger than 
1 year was 50% of that used in the older children. 
In contrast, the dosage used in 1−3-year-olds was 
relatively high. Dose modification in this age group 
should be considered in order to decrease the inci-
dence of VOD. Furthermore, an uneventful course 
of VAC therapy does not guarantee the absence of 
VOD in subsequent courses: two-thirds of VOD oc-
curred during the second or third courses of VAC 
therapy.10 In our 21-month-old patient, VOD devel-
oped during the second cycle, consistent with the 
above findings.
Efficient therapy for VOD is not yet well estab-
lished.1,2,7 Supportive treatment with blood com-
ponent replacement is vital. Anticoagulation therapy, 
such as tissue-plasminogen activator with or with-
out concurrent heparin, might be beneficial, but is 
associated with significant risk of life-threatening 
bleeding.2 Prostaglandin E1, glutamine, and vitamin 
E have been used, albeit in mostly anecdotal reports 
and in small case series.11 Defibrotide has been re-
ported to show promise in the treatment of VOD, 
and complete resolution of VOD was seen in 36% of 
patients, with 35% survival at Day + 100.12 No severe 
hemorrhage or serious toxicities were reported, 
but defibrotide is not universally available.
Corticosteroids, which are potent inhibitors of 
cytokine production, have been used as prophy-
laxis for graft-versus-host disease for a long time.3 
Khoury et al used HDMT to treat regimen-related 
hepatic toxicity after bone marrow transplantation 
and observed a 61% response rate.13 In their study, 
however, some patients were treated early, after 
the development of hyperbilirubinemia, and in the 
absence of other criteria of VOD. Moreover, earlier 
use of corticosteroids may increase the risk of su-
perimposed infections. Akyüz et al also used HDMT 
to treat hepatic VOD arising after conventional 
chemotherapy in a child with Wilms’ tumor14 who 
had previously received abdominal irradiation. 
HDMT was given to our patient because of impend-
ing respiratory failure after intensive supportive 
care. AST, ALT, and bilirubin levels increased ini-
tially and gradually declined 3 days later, implying 
a response to HDMT. No apparent complications, 
such as hyperglycemia, hypertension, or bleeding, 
were observed during the remaining treatment 
course. However, our patient’s recovery could be at-
tributed partly, if not entirely, to spontaneous im-
provement following meticulous supportive care. 
In a large series report, 10 of 821 patients with rhab-
domyosarcoma developed VOD after receiving con-
ventional chemotherapy.15 One of the 10 patients 
died and one developed portal hypertension. Five 
of the remaining eight patients were switched to 
other regimens, while the other three patients con-
tinued to receive the same regimen but at 25% of 
the initial administrated dose. The dose was slowly 
escalated to the full dose if the patients showed 
no signs of hepatotoxicity. None of these eight pa-
tients developed recurrent VOD. The importance 
of good supportive care and avoidance of aggres-
sive diuresis cannot be overemphasized. Randomized 
controlled trials are required to determine the 
efficacy of HDMT.
In summary, we have reported our experience 
of using HDMT to treat hepatic VOD in a child with 
rhabdomyosarcoma who was receiving conventional 
chemotherapy. The efficacy of HDMT and the timing 
of its administration deserve further investigation.
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